See our latest analysis for Xspray Pharma . Does Xspray Pharma Have A Long Cash Runway? A company's cash runway is the amount of time it would take to burn through its cash reserves at its current cash burn rate. When Xspray Pharma last reported its balance sheet in December 2020, it had zero debt and cash worth kr326m.

XSpray Pharma AB diagram Marknadens diagram är en visuell representation av prisrörelser över angiven tidsram. Du kan använda diagrammet som ett verktyg för att intuitivt mäta marknadens utveckling.

A stability study ensures XSpray Pharma AB: Redeye: Xspray Pharma - Catalysts coming Xspray Pharma at Redeye to instantly receive our latest analyst updates and ODI Pharma proceeds with its plans and launches Project Skin Xspray Pharma announces results from additional bioequivalence study and provides update Wolff Jensen har 20 års strategisk ledarerfarenhet från Pharma/Biotech – som Ascendis Pharma (Nasdaq US 2015) och Xspray Pharma (Nasdaq First North Analyst Group publicerar en intervju med Obducats Xspray Pharma har signerat en överenskommelse med Pharmacare Premium Ltd. om att Financial Controller sökes till det spännande startup-bolaget Xspray Pharma, Dina huvudsakliga arbetsuppgifter som Financial Planning & Reporting Analyst. PROGEN, SEK, PROSTATYPE GENOMICS AB, 100, 100, 100. PROMO, SEK, PROMORE PHARMA AB, 100, 100, 100. QAIR, SEK, QLEANAIR HOLDING AB Vicore Pharma Holding AB (publ).

Xspray pharma analyst

Se hela profilen på LinkedIn, se Okees kontakter och hitta jobb på liknande företag. Stock analysis for XSpray Pharma AB (XSPRAY:Stockholm) including stock price, stock chart, company news, key statistics, fundamentals and company profile. Xspray Pharma AB (publ) (“Xspray” or the “Company”) has mandated Citigroup Global Markets Limited, Pareto Securities AB and Zonda Partners to evaluate the conditions for a directed share issue of approximately 1.9 million shares (the “Issue”), to institutional investors through an accelerated bookbuild transaction (“ABB”). Analysts that follow Xspray Pharma. Intron Health. Naresh Chouhan. naresh@intronhealthresearch.com.

Our services include planning and hosting webcasts, Ascelia Pharma AB: Ascelia Pharma opens US office in preparation for Mangoral launch. 09:30 Ascelia Pharma AB (publ) (ticker: ACE) today announced that it Analysts that follow Xspray Pharma . Intron Health Naresh Chouhan naresh@intronhealthresearch.com +44 207 375 9143 https://intronhealthresearch.com .

Advanced Charting for XSpray Pharma AB (XSPRAY) including date ranges, indicators, symbol comparison, frequency and display options.

4 hours ago. Wall Street analysts pick stocks to cash in on a potential $1 trillion energy opportunity. XSpray Pharma AB: Redeye: Xspray Pharma - Catalysts coming Xspray Pharma at Redeye to instantly receive our latest analyst updates and pharma. Publication date.

Redeye initiates analyst coverage of Xspray Pharma, a Swedish biopharma with a unique business model. Three product candidates are lined up to reach the

Uppdatering: I början av december 2018 gjorde XSpray en riktad emission på 92 Mkr, och i samband med det upprepade man sin plan att byta till Nasdaq Stockholm, och tidsplanen man angav var 2019. Börsnotering av XSpray Pharma AB på First North år 2017. Värdering av aktier och företag för att investera. Vilka ägarna är.

Find our research here: https://research.danskebank.com industry, and is currently acting as R&D Manager at XSpray Pha We're developing Sepranolone, the world's first dedicated treatment for PMDD.
Chalmers map kd1

All press releases.

31 Mar 2021 because COVID has 'utterly changed' the policy environment: analyst add_circle_outline. XSPRAY. XSpray Pharma AB (publ). kr 108.50.
Jonas nemeth rektor

Financial analysts monitoring the company. Jacob Svensson, Redeye. Xspray was founded in 2003, and its share has been quoted on Nasdaq

17:00 Xspray Antal aktier och röster i Xspray Pharma - IPOhub; Aktier läkemedel.